National Centre for Pharmacoeconomics

National Centre for

NCPE Ireland

Apalutamide is indicated for adult men for the treatment of metastatic hormone-sensitive prostate cancer in combination with androgen deprivation therapy.


NCPE Assessment Process Complete
Rapid review commissioned 26/02/2020
Rapid review completed 23/03/2020
Rapid Review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of apalutamide for this indication compared with the current standard of care.